London · Delayed Price · Currency is GBP · Price in GBX Futura Medical Earnings Call Transcripts
Fiscal Year 2025
-
2025 saw a strategic reset with sharply lower revenues, cost base alignment, and a focus on disciplined cash management. Eroxon Intense and WSD4000 development advanced, with launches targeted for 2027 and 2028, and APAC expansion prioritized.
-
H1 2025 saw disappointing repeat sales and revenue, leading to a significant downgrade in full-year expectations and a strategic review. Cash runway extends into January 2026, with new product launches and financing options under active consideration.
Fiscal Year 2024
-
Achieved first profit in 2024 with GBP 14 million revenue and 70% gross margin, driven by Eroxon launches in 15+ countries. Pipeline products advancing, but sales guidance revised lower due to early-stage market dynamics and product effectiveness in younger men.
-
Reported first-ever profit and over 300% revenue growth in H1 2024, driven by Eroxon’s rollout in 10+ countries and upcoming U.S. launch with Haleon. Gross margin was 44%, with significant manufacturing investments and updated guidance expected.